The effect of captopril on progression of retinopathy in type 2 diabetes

Diabetes Technology and Therapeutics

Volumn 11, Issue 11, 2009, Pages 711-715

  Khamseh, Mohammad E ^a   Safarnejad, Bahareh ^a   Baradaran, Hamid R ^a,b  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b BOND UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETIC HYPERTENSION; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DRUG EFFECT; EYE EXAMINATION; EYE PROTECTION; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MYDRIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHTHALMOSCOPY; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; BODY MASS INDEX; CAPTOPRIL; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS;

EID: 70449627541     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0073     Document Type: Article

References (29)

1. Diabetes Fact Sheet Number 312. Geneva: World Health Organization, 2006. http:==www.who.int=mediacentre= factsheets=fs312=en= (accessed July 25, 2009).
2. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL 3rd, Klein R: Diabetic retinopathy. Diabetes Care 1998;21:143-156. (Pubitemid 28030402)
3. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527-532. (Pubitemid 14127839)
4. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR: UKPDS 50: Risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156-163.
5. Klein R, Klein BE, Moss SE, Davis MD, DeMets D: The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-526. (Pubitemid 14127838)
6. Sjølie AK, Stephenson J, Aldington S, Kohner E, Janka H, Stevens L, Fuller J: The EURODIAB IDDM Complications Study Group. Retinopathy and vision loss in insulin dependent diabetics in Europe. Ophthalmology 1997;104:252-260.
7. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-713.
8. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14- year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-1815.
9. Phipps JA, Wilkinson-Berka JL, Fletcher EL: Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol. Invest Ophthalmol Vis Sci 2007;48:927-934.
10. Tamura K, Umemura S, Nyui N, Nyui N, Hibi K, Ishigami T, Kihara M, Toya Y, Ishii M: Activation of angiotensinogen gene in cardiac myocytes by angiotensin II and mechanical stretch. Am J Physiol 1998;275:R1-R9.
11. Suzuma I, Hata Y, Clermont A, Pokras F, Rook SL, Suzuma K, Feener EP, Aiello LP: Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension. Diabetes 2001;50:444-454.
12. Gilbert RE, Vranes D, Berka JL, Kelly DJ, Cox A, Wu LL, Stacker SA, Cooper ME: Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 1998;78:1017-1027.
13. Goa KL, Haria M, Wilde MI: Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus. Drugs 1997;53:1081-1105
14. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin- Dependent Diabetes Mellitus. Lancet 1998;351:28-31.
15. Zheng Z, Chen H, Xu X, Li C, Gu Q: Effects of angiotensinconverting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy. Exp Eye Res 2007;84:745-752.
16. White JR, Campbell RK: PDA=PDR Medications for the Treatment of Diabetes. Alexandria, VA: American Diabetes Association, 2008.
17. Houben AJ, Canoy MC, Paling HA, Derhaag PJ, de Leeuw PW: Quantitative analysis of retinal vascular changes in essential and renovascular hypertension. J Hypertens 1995;13: 1729-1733.
18. Kohler K, Wheeler-Schilling T, Jurklies B, Guenther E, Zrenner E: Angiotensin II in the rabbit retina. Vis Neurosci 1997;14:63-71.
19. Moravski CJ, Skinner SL, Stubbs AJ, Sarlos S, Kelly DJ, Cooper ME, Gilbert RE, Wilkinson-Berka JL: The reninangiotensin system influences ocular endothelial cell proliferation in diabetes: Transgenic and interventional studies. Am J Pathol 2003;162:151-160.
20. Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, Lim SC, Tai ES, Mitchell P: Prevalence and risk factors for diabetic retinopathy: The Singapore Malay Eye Study. Ophthalmology 2008;115:1869-1875.
21. Rodriguez-Fontal M, Kerrison JB, Alfaro DV, Jablon EP: Metabolic control and diabetic retinopathy. Curr Diabetes Rev 2009;5:3-7.
22. Raman R, Rani PK, Reddi Rachepalle S, Gnanamoorthy P, Uthra S, Kumaramanickavel G, Sharma T: Prevalence of diabetic retinopathy in India: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study report 2. Ophthalmology 2009;116:311-318.
23. Pirart J: [Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author's transl)]. Diabete Metab 1977;3:245-256.
24. Raman R, Rani PK, Gnanamoorthy P, Sudhir RR, Kumaramanikavel G, Sharma T: Association of obesity with diabetic retinopathy: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study (SN-DREAMS Report no. 8). Acta Diabetol 2009 Mar 27 [Epub ahead of print].
25. Hosseini SM, Maracy MR, Amini M, Baradaran HR: A risk score development for diabetic retinopathy screening in Isfahan-Iran. J Res Med Sci 2009;14:105-110.
26. Faghih-Imani E, Amini M, Adibi P: [Silent ischemia in type II diabetic patients: A study of EKG changes]. ARYA J 2005; 1:89-93.
27. Safaei H, Amini M, Behrooz J: [Cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus]. Iran Endocrinol Metab J 2006;8:31-38.
28. Amini N, Oroumcheh S, Taghavi F: Prevalence of hypertension among 780 diabetic patients referred to Yazd Diabetes Centre in 2002-2003 [Dissertation]. Yazd, Iran: Yazd University of Medical Sciences, 1993.
29. Gilbert RE, Kelly DJ, Cox AJ, Wilkinson-Berka JL, Rumble JR, Osicka T, Panagiotopoulos S, Lee V, Hendrich EC, Jerums G, Cooper ME: Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000;43:1360-1367.